Drug Search Results
More Filters [+]

AZD-6423

Alternative Names: azd-6423, azd6423, azd 6423
Latest Update: 2014-04-04
Latest Update Note: Clinical Trial Update

Product Description

NMDA modulator for suicidal ideation

Mechanisms of Action: NMDA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-6423

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AZD6423

P1

Completed

Healthy Volunteers

2014-03-01

Recent News Events

Date

Type

Title